193 related articles for article (PubMed ID: 35973670)
1. High Risk of Recurrence of Malignancy Noted in Four-day rATG Regimen After Allogeneic PBSCT From Matched Sibling Donors.
Wang N; Wang H; Fang S; Du J; Huang S; Li F; Jin X; Jia M; Xu L; Dou L; Liu D
Transplant Cell Ther; 2022 Nov; 28(11):769.e1-769.e9. PubMed ID: 35973670
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy analysis of anti-thymocyte globulin regimens with different timing strategies for matched sibling donor hematopoietic stem cell transplantation].
Du JS; Wang HT; Dou LP; Wang N; Li F; Jin XS; Liu DH
Zhonghua Xue Ye Xue Za Zhi; 2023 Aug; 44(8):660-666. PubMed ID: 37803840
[No Abstract] [Full Text] [Related]
3. Reduced risk of chronic GVHD by low-dose rATG in adult matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies.
Dou L; Hou C; Ma C; Li F; Gao X; Huang W; Wang S; Gao C; Yu L; Liu D
Ann Hematol; 2020 Jan; 99(1):167-179. PubMed ID: 31828376
[TBL] [Abstract][Full Text] [Related]
4. Optimal Active Anti-Thymocyte Globulin Exposure Associated with Minimum Risk of Virus Reactivation and Comparable Acute Graft-Versus-Host Disease Under Adult Myeloablative Haploidentical Peripheral Blood Stem Cell Transplantation.
Wang H; Zhao Y; Fang S; Wang L; Peng B; Yang J; Wang N; Du J; Li F; Jin X; Luan S; Wu X; Dou L; Liu D
Transplant Cell Ther; 2022 Jun; 28(6):332.e1-332.e10. PubMed ID: 35314377
[TBL] [Abstract][Full Text] [Related]
5. Targeted dosing of anti-thymocyte globulin in adult unmanipulated haploidentical peripheral blood stem cell transplantation: A single-arm, phase 2 trial.
Wang H; Wang N; Wang L; Du J; Li F; Shao Y; Peng B; Luan S; Wang L; Jin X; Gao C; Dou L; Liu D
Am J Hematol; 2023 Nov; 98(11):1732-1741. PubMed ID: 37706580
[TBL] [Abstract][Full Text] [Related]
6. Reduced Risk of Chronic Graft-Versus-Host Disease (cGVHD) by Rabbit Anti-Thymocyte Globulin (ATG) in Patients Undergoing Matched Sibling Donor Transplantation in Hematological Malignancies.
Fang S; Wang N; Wang L; Du J; Yang J; Wen Y; Wei Y; Qian K; Wang H; Jiao Y; Gao C; Dou L
Ann Transplant; 2022 Oct; 27():e937356. PubMed ID: 36217289
[TBL] [Abstract][Full Text] [Related]
7. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
[TBL] [Abstract][Full Text] [Related]
8. Low-dose anti-thymocyte globulin plus low-dose post-transplant cyclophosphamide-based regimen for prevention of graft-versus-host disease after haploidentical peripheral blood stem cell transplants: a large sample, long-term follow-up retrospective study.
Li X; Yang J; Cai Y; Huang C; Xu X; Qiu H; Niu J; Zhou K; Zhang Y; Xia X; Wei Y; Shen C; Tong Y; Dong B; Wan L; Song X
Front Immunol; 2023; 14():1252879. PubMed ID: 37954615
[TBL] [Abstract][Full Text] [Related]
9. [Application of low-dose ATG for GVHD prophylaxis in patients undergoing PBSCT aged over forty years old].
Liang C; Jiang EL; Yao JF; Ma QL; Zhai WH; Pang AM; Huang Y; Wei JL; Feng SZ; Han MZ
Zhonghua Xue Ye Xue Za Zhi; 2018 Apr; 39(4):292-298. PubMed ID: 29779324
[No Abstract] [Full Text] [Related]
10. Clinical Benefit of Low-Dose Antithymocyte Globulin-Thymoglobulin as Graft-versus-Host Disease Prophylaxis in Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplantation from HLA-Identical Donors.
Takeuchi Y; Miyao K; Negishi S; Ohara F; Motegi K; Wakabayashi H; Yokota H; Kuwano S; Sawa H; Inagaki Y; Sawa M
Transplant Cell Ther; 2023 May; 29(5):325.e1-325.e10. PubMed ID: 36736783
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Outcomes of Haploidentical Peripheral Blood Stem Cell Transplantation Supported by Third-Party Cord Blood Versus Human Leukocyte Antigen-Matched Sibling Peripheral Blood Stem Cell Transplantation in Hematologic Malignancy Patients.
Cheng T; Chen Y; Liu Y; Ma X; Zeng C; Chen X; Wang S; Xu Y
Front Oncol; 2022; 12():922120. PubMed ID: 35912178
[TBL] [Abstract][Full Text] [Related]
12. [The impact of donor-to-recipient gender compatibility on outcomes of haploid hematopoietic stem cell transplantation in patients with hematological malignancies].
Hu SS; Wu YB; Zhu PP; Shi JM; Yu J; Zhao YM; Lai XY; Liu LZ; Fu HR; Huang H; Luo Y
Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):992-1002. PubMed ID: 36709104
[No Abstract] [Full Text] [Related]
13. Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2020 Aug; 99(8):1883-1893. PubMed ID: 32572523
[TBL] [Abstract][Full Text] [Related]
14. Antithymocyte Globulin Potentially Could Overcome an Adverse Effect of Acute Graft-versus-Host Disease in Matched-Related Peripheral Blood Stem Cell Transplantation.
Miyao K; Kuwatsuka Y; Murata M; Nagafuji K; Teshima T; Takeuchi Y; Shiratori S; Najima Y; Uchida N; Tanaka M; Sawa M; Ota S; Fukuda T; Ozawa Y; Kako S; Kawakita T; Ara T; Tanaka J; Kanda Y; Atsuta Y; Kanda J; Terakura S;
Transplant Cell Ther; 2022 Mar; 28(3):153.e1-153.e11. PubMed ID: 34954151
[TBL] [Abstract][Full Text] [Related]
15. Comparable outcomes of allogeneic peripheral blood versus bone marrow hematopoietic stem cell transplantation from a sibling donor for pediatric patients.
Kim BK; Hong KT; Choi JY; Kim H; Park HJ; Kang HJ
Ann Hematol; 2024 Jun; 103(6):2051-2058. PubMed ID: 38594416
[TBL] [Abstract][Full Text] [Related]
16. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies.
Dou L; Wang L; Li X; Liu Y; Li F; Wang L; Gao X; Huang W; Wang S; Gao C; Yu L; Liu D
Medicine (Baltimore); 2021 Feb; 100(8):e24725. PubMed ID: 33663084
[TBL] [Abstract][Full Text] [Related]
17. Lower Absolute Lymphocyte Count Before Conditioning Predicts High Relapse Risk in Patients After Haploidentical Peripheral Blood Stem Cell Transplantation With Low Dose Anti-Thymocyte Globulin/Post-Transplant Cyclophosphamide for GvHD Prophylaxis.
Zhou X; Cai Y; Yang J; Tong Y; Qiu H; Huang C; Zhou K; Xu X; Niu J; Xia X; Zhang Y; Shen C; Wei Y; Song X; Wan L
Cell Transplant; 2022; 31():9636897221079739. PubMed ID: 35225024
[TBL] [Abstract][Full Text] [Related]
18. Anti-thymocyte globulin improves survival free from relapse and graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia-negative acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the EBMT.
Czerw T; Labopin M; Giebel S; Socié G; Volin L; Fegueux N; Masszi T; Blaise D; Chaganti S; Cornelissen JJ; Passweg J; Maertens J; Itälä-Remes M; Wu D; Mohty M; Nagler A
Cancer; 2018 Jun; 124(12):2523-2533. PubMed ID: 29603136
[TBL] [Abstract][Full Text] [Related]
19. Modified combination of anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) as compared with standard ATG protocol in haploidentical peripheral blood stem cell transplantation for acute leukemia.
Barkhordar M; Kasaeian A; Janbabai G; Kamranzadeh Fumani H; Tavakoli S; Rashidi AA; Mousavi SA; Ghavamzadeh A; Vaezi M
Front Immunol; 2022; 13():921293. PubMed ID: 35990618
[TBL] [Abstract][Full Text] [Related]
20. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
